RPG Life Sciences Limited (RPGLIFE.NS)
INR 2089.8
(-0.07%)
INR 2089.8
(-0.07%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.29 Billion INR | 26.08% |
| 2022 | 881 Million INR | 24.54% |
| 2021 | 707.4 Million INR | 31.83% |
| 2020 | 536.6 Million INR | 24.94% |
| 2019 | 429.5 Million INR | 123.81% |
| 2018 | 191.9 Million INR | -26.7% |
| 2017 | 261.8 Million INR | 48.58% |
| 2016 | 176.2 Million INR | 21.43% |
| 2015 | 145.1 Million INR | 402.08% |
| 2014 | 28.9 Million INR | 133.06% |
| 2013 | 12.4 Million INR | -84.3% |
| 2012 | 79 Million INR | -8.35% |
| 2011 | 86.2 Million INR | -62.92% |
| 2010 | 232.49 Million INR | 2.46% |
| 2009 | 226.9 Million INR | 34.06% |
| 2008 | 169.25 Million INR | -5.05% |
| 2007 | 178.25 Million INR | -17.13% |
| 2006 | 215.09 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 337.8 Million INR | 108.13% |
| 2023 Q2 | 348.9 Million INR | 24.47% |
| 2023 Q1 | 280.3 Million INR | 116.78% |
| 2023 FY | 1.11 Billion INR | 26.08% |
| 2023 Q4 | 162.3 Million INR | -54.51% |
| 2023 Q3 | 356.8 Million INR | 2.26% |
| 2022 Q2 | 270.9 Million INR | 7.37% |
| 2022 Q4 | 129.3 Million INR | -49.9% |
| 2022 FY | 881 Million INR | 24.54% |
| 2022 Q1 | 252.3 Million INR | 159.3% |
| 2022 Q3 | 258.1 Million INR | -4.72% |
| 2021 Q4 | 97.3 Million INR | -51.76% |
| 2021 Q2 | 218.1 Million INR | 14.85% |
| 2021 Q3 | 201.7 Million INR | -7.52% |
| 2021 FY | 707.4 Million INR | 31.83% |
| 2021 Q1 | 189.9 Million INR | 89.71% |
| 2020 Q2 | 149.2 Million INR | 17.57% |
| 2020 FY | 536.6 Million INR | 24.94% |
| 2020 Q3 | 171.1 Million INR | 14.68% |
| 2020 Q4 | 100.1 Million INR | -41.5% |
| 2020 Q1 | 126.9 Million INR | 34.14% |
| 2019 Q2 | 122.5 Million INR | 7.17% |
| 2019 FY | 429.5 Million INR | 123.81% |
| 2019 Q4 | 94.6 Million INR | -12.16% |
| 2019 Q3 | 107.7 Million INR | -12.08% |
| 2019 Q1 | 114.3 Million INR | 221.07% |
| 2018 Q2 | 40.9 Million INR | 26.63% |
| 2018 Q1 | 32.3 Million INR | -34.08% |
| 2018 Q3 | 82.2 Million INR | 100.98% |
| 2018 Q4 | 35.6 Million INR | -56.69% |
| 2018 FY | 191.9 Million INR | -26.7% |
| 2017 FY | 261.8 Million INR | 48.58% |
| 2017 Q3 | 84.2 Million INR | -1.17% |
| 2017 Q4 | 49 Million INR | -41.81% |
| 2017 Q1 | 13.4 Million INR | -14.65% |
| 2017 Q2 | 85.2 Million INR | 535.82% |
| 2016 Q4 | 15.7 Million INR | 11.35% |
| 2016 Q3 | 14.1 Million INR | -67.06% |
| 2016 Q2 | 42.8 Million INR | -57.58% |
| 2016 FY | 176.2 Million INR | 21.43% |
| 2016 Q1 | 100.9 Million INR | 305.22% |
| 2015 Q4 | 24.9 Million INR | -52.3% |
| 2015 Q2 | 33.1 Million INR | 7.47% |
| 2015 Q3 | 52.2 Million INR | 57.7% |
| 2015 Q1 | 30.8 Million INR | -32.9% |
| 2015 FY | 145.1 Million INR | 402.08% |
| 2014 Q1 | 15.2 Million INR | 164.96% |
| 2014 Q4 | 45.9 Million INR | 29.3% |
| 2014 Q3 | 35.5 Million INR | 152.44% |
| 2014 Q2 | -67.7 Million INR | -545.39% |
| 2014 FY | 28.9 Million INR | 133.06% |
| 2013 Q3 | -51 Million INR | -360.2% |
| 2013 Q1 | 67.2 Million INR | 21.96% |
| 2013 Q2 | 19.6 Million INR | -70.83% |
| 2013 Q4 | -23.4 Million INR | 54.12% |
| 2013 FY | 12.4 Million INR | -84.3% |
| 2012 Q1 | 45.3 Million INR | 0.0% |
| 2012 FY | 79 Million INR | -8.35% |
| 2012 Q3 | -43.9 Million INR | -295.11% |
| 2012 Q2 | 22.5 Million INR | -50.33% |
| 2012 Q4 | 55.1 Million INR | 225.51% |
| 2011 FY | 86.2 Million INR | -62.92% |
| 2010 FY | 232.49 Million INR | 2.46% |
| 2009 FY | 226.9 Million INR | 34.06% |
| 2008 FY | 169.25 Million INR | -5.05% |
| 2007 FY | 178.25 Million INR | -17.13% |
| 2006 FY | 215.09 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 621.02 Million INR | -269.114% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -10997.502% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 68.274% |
| FDC Limited | 3.03 Billion INR | 24.44% |
| Gufic Biosciences Limited | 2.89 Billion INR | 20.786% |
| Hikal Limited | 1.49 Billion INR | -53.413% |
| Ind-Swift Laboratories Limited | 2 Billion INR | -14.1% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 53.618% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -1001.802% |
| Medico Remedies Limited | 277.11 Million INR | -727.193% |
| Nectar Lifesciences Limited | 3.89 Billion INR | 41.081% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -315.581% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Shilpa Medicare Limited | 3.76 Billion INR | 39.06% |
| Sigachi Industries Limited | 1.47 Billion INR | -55.527% |
| Themis Medicare Limited | 1.3 Billion INR | -75.911% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Venus Remedies Limited | 534.65 Million INR | -328.747% |
| Wanbury Limited | 1.7 Billion INR | -34.272% |
| ZIM Laboratories Limited | 1.09 Billion INR | -108.749% |
| Lupin Limited | 27.75 Billion INR | 91.742% |
| Innova Captab Limited | 2.53 Billion INR | 9.517% |
| Ind-Swift Limited | 1.22 Billion INR | -86.979% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 97.806% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 159.495% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 48.763% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -8248.387% |
| Morepen Laboratories Limited | 4.17 Billion INR | 45.079% |
| Laurus Labs Limited | 3.94 Billion INR | 41.947% |
| Aarti Drugs Limited | 7.14 Billion INR | 67.934% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 74.471% |
| Alembic Limited | 767.77 Million INR | -198.566% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 60.19% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 64.747% |
| Vaishali Pharma Limited | 6.29 Million INR | -36320.4% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 26.719% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -970.968% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 55.824% |
| Eris Lifesciences Limited | 5.18 Billion INR | 55.762% |
| Windlas Biotech Limited | 1.29 Billion INR | -76.481% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 97.802% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | -20.247% |
| Orchid Pharma Limited | 2.36 Billion INR | 2.913% |
| Albert David Limited | 1.33 Billion INR | -71.778% |
| Hester Biosciences Limited | 364.77 Million INR | -528.423% |
| Sakar Healthcare Limited | 495.5 Million INR | -362.618% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 50.25% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 17.721% |
| Divi's Laboratories Limited | 18.31 Billion INR | 87.481% |
| Mankind Pharma Limited | 40.86 Billion INR | 94.391% |
| Neuland Laboratories Limited | 5.31 Billion INR | 56.896% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 69.605% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 94.95% |
| Wockhardt Limited | 140 Million INR | -1537.357% |
| Bal Pharma Limited | 214.56 Million INR | -968.328% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 96.615% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -86.214% |
| Alkem Laboratories Limited | 19.46 Billion INR | 88.222% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 88.351% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -864.525% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -80876.365% |
| Granules India Limited | 6.52 Billion INR | 64.887% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Ipca Laboratories Limited | 29.59 Billion INR | 92.255% |
| Brooks Laboratories Limited | -72.25 Million INR | 3272.646% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -819.675% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 90.952% |
| NATCO Pharma Limited | 25.96 Billion INR | 91.171% |
| Suven Life Sciences Limited | -1.22 Billion INR | 287.001% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 56.135% |
| Indoco Remedies Limited | 1.52 Billion INR | -50.374% |
| Alpa Laboratories Limited | 61.51 Million INR | -3626.408% |
| Lasa Supergenerics Limited | -458 Million INR | 600.497% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 155.705% |